PEGylated Anti-MUC1 Aptamer-Doxorubicin Complex for Targeted Drug Delivery to MCF7 Breast Cancer Cells
✍ Scribed by Lihan Tan; Koon Gee Neoh; En-Tang Kang; Woo Seok Choe; Xiaodi Su
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 301 KB
- Volume
- 11
- Category
- Article
- ISSN
- 1616-5187
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Targeted drug delivery is especially important in cancer treatment as many anti‐cancer drugs are non‐specific and highly toxic to both cancer and normal cells. The targeted drug delivery of DOX to the MUC1‐expressing breast cancer cell line (MCF7) was obtained using APT as a carrier. Modification of the APT‐DOX complex by PEG increases the survivability of the macrophage control (RAW 264.7) by about six‐fold as compared to free DOX treatment without significantly affecting the cytotoxicity toward the target cell line. Thus, PEG‐APT‐DOX is potentially a new therapeutic agent for targeted drug delivery to MUC1‐expressing cell lines.magnified image